Landos, Johns Hopkins Partner to Advance Potential MS Oral Therapy

Landos, Johns Hopkins Partner to Advance Potential MS Oral Therapy

304494

Landos, Johns Hopkins Partner to Advance Potential MS Oral Therapy

Landos Biopharma has entered into a research partnership with Johns Hopkins University School of Medicine focused on advancing LABP-66 as a potential oral, once-daily therapy for multiple sclerosis (MS) and other disorders, the company announced. LABP-66 is a lab-made molecule that activates NLRX1, a receptor that is key in regulating central nervous system inflammation and preventing autoimmunity, both features of MS. A Phase 1 clinical trial (NCT04458805) in healthy volunteers showed that NX-13 — a molecule also designed…

You must be logged in to read/download the full post.